TY - JOUR JO - Reumatologia/Rheumatology SN - 0034-6233 VL - 52 IS - 4 PY - 2014 ID - Marcinowska-Suchowierska2014 TI - Pharmacological therapy of osteoporosis with bisphosphonates – for whom, what kind, and for how long? AB - For many years bisphosphonates (BS) have played an important role in the treatment of postmenopausal osteoporosis. Additionally, they have recently been used in men and induced osteoporosis by administering glucocorticoids and some other secondary osteoporosis. Designing pharmacologically equivalent BS substance administered orally once a week or once a month allowed to reduce side effects related to the digestive system. Availability of intravenous BS substance resulted in a more frequent occurrence of the acute phase reactions. Recently a relation has been noticed between the use of BS and the occurrence of complications including osteonecrosis of the jaw and atypical subtrochanteric fractures. In this article the authors present current knowledge regarding BS treatment in osteoporosis and some adverse effects related to its long-term use. This information will help to optimize the length of treatment with BS and to make a decision about potential discontinuation of BS treatment. AU - Marcinowska-Suchowierska, Ewa AU - Walicka, Magdalena SP - 238 EP - 246 DA - 2014 DO - 10.5114/reum.2014.44703 UR - http://dx.doi.org/10.5114/reum.2014.44703 ER -